Tizanidine
| Evidence Level: L2 | Predicted Indications: 6 |
Table of Contents
Tizanidine: From Muscle Spasticity to Migraine Prevention
One-Sentence Summary
Tizanidine is a centrally acting α2-adrenergic receptor agonist, conventionally used as a muscle relaxant for spasticity. The TxGNN model predicts it may be effective for Migraine Disorder prevention, with 2 clinical trials (including an ongoing Phase 3 RCT) and 20 publications currently supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Muscle spasticity/spasm (central α2-agonist muscle relaxant) — not currently marketed in India, so no formal approved indication text is available in the regulatory record |
| Predicted New Indication | Migraine disorder |
| TxGNN Prediction Score | 99.79% |
| Evidence Level | L2 |
| India Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Formal mechanism-of-action documentation for tizanidine is not available in this evidence pack. However, the underlying pharmacological rationale is captured in the repurposing evidence: tizanidine is a centrally acting α2-adrenergic receptor agonist that inhibits excitatory neurotransmitter release from the locus coeruleus and the trigeminovascular system.
This mechanism is analogous to clonidine, another α2-agonist that has long been used off-label as a prophylactic agent for chronic daily headache and migraine. The class-effect logic — α2-agonists dampening central noradrenergic and trigeminovascular hyperexcitability — provides a plausible biological bridge between tizanidine’s established muscle-relaxant use and its predicted role in migraine prevention.
This is further supported by a substantial body of literature (dating back to 2001–2002) specifically evaluating tizanidine in chronic daily headache/migraine prophylaxis, culminating in a currently recruiting Phase 3 RCT designed explicitly to test this indication.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT05484349 | Phase 3 | Recruiting | 189 | Multicenter, randomized, double-blind, placebo-controlled study evaluating oral tizanidine HCl for preventing migraine attacks in adult episodic migraine patients (with/without aura); pivotal trial, results not yet available |
| NCT02403687 | N/A | Completed | 300 | 24-week observational study on analgesic efficacy (focused on topical NSAIDs); only moderately relevant to tizanidine-specific migraine use |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 12167135 | 2002 | RCT | Headache | Double-blind, placebo-controlled multicenter study assessing tizanidine as adjunctive prophylactic therapy for chronic daily headache/migraine |
| 11318882 | 2001 | Open-label study | Headache | Dose-titration study of tizanidine tablets for prophylaxis of chronic daily headache; establishes efficacy and tolerability |
| 31365643 | 2019 | Guideline/Consensus | Arquivos de neuro-psiquiatria | Brazilian Headache Society consensus on chronic migraine treatment |
| 40983294 | 2025 | Preclinical/Formulation | J Control Release | Supramolecular co-crystal of tizanidine + meloxicam shows synergistic anti-migraine efficacy |
| 12696998 | 2003 | Review | CNS Drugs | Reviews baclofen, tizanidine and botulinum toxin A as preventative treatments for migraine and tension-type headache |
| 15115635 | 2004 | Review | Curr Pain Headache Rep | Reviews emerging prophylactic migraine options including tizanidine |
| 17115988 | 2006 | Review | Headache | Prophylactic treatment of chronic daily headache, includes tizanidine among evidence-supported agents |
| 21770931 | 2011 | Review | Headache | Reviews clinical trials on chronic migraine prophylaxis, including tizanidine |
| 23293866 | 2013 | Review | Headache | Rational approach to chronic migraine management; lists tizanidine among agents with demonstrated efficacy |
| 11903539 | 2002 | Case study | Headache | Low-dose tizanidine combined with NSAIDs for detoxification from analgesic rebound headache |
India Market Information
Tizanidine is currently not marketed in India (0 registered licenses). No product authorization, dosage form, or approved indication text is available for this review.
Safety Considerations
Drug Interactions: Tizanidine has 249 documented drug-drug interactions in the source database. Selected clinically significant ones include:
- Major: Famotidine, Morphine, Cimetidine, Dolasetron, Obeticholic acid
- Moderate: Hyoscyamine, Loperamide, Atropine, Clarithromycin, Dicyclomine, Difenoxin, Dronabinol, Palonosetron, Sodium sulfate, Nabilone, Naltrexone, Levofloxacin, Metoclopramide, Picosulfuric acid, Polyethylene glycol (3350 with electrolytes)
Given the volume (249 total interactions), a full interaction check against the patient’s concurrent medications is recommended before use.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: A pivotal Phase 3 RCT (NCT05484349) is actively recruiting to directly test tizanidine for migraine prevention, and this is reinforced by a long-standing literature base including an earlier completed placebo-controlled trial (Saper 2002) and consistent class-effect mechanistic rationale (α2-agonist, analogous to clonidine). However, the key confirmatory trial has not yet reported results, and the drug is not currently marketed in India.
To proceed, the following is needed:
- Await completion and results of NCT05484349 (expected completion 2025-12-25)
- Obtain formal TFDA/India labeling data — key warnings and contraindications are currently a blocking data gap
- Obtain confirmed mechanism-of-action documentation from DrugBank
- Establish a market registration/access pathway in India, since the drug currently has no local marketing authorization
- Full drug-interaction review given the high interaction count (249 documented)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.